Enzyme News and Research

RSS

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

The findings of a new study showed that the intranasal SpyCage vaccine platform can be protective against SARS-CoV-2 and may prove to be a versatile and adaptable modality for the formulation of intranasal vaccines that target respiratory pathogens.

31 Oct 2022

Ceria nanoparticles interfere with biological processes just like native enzymes

Bacteria love moist surfaces. Once they have settled there, they do not live as solitary organisms but form larger communities that are embedded in a protective film.

28 Oct 2022

Researchers propose origin-of-life molecule as therapeutic target for tailored cancer therapies

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cancer.

28 Oct 2022

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Researchers investigated whether immunity against seasonal human coronavirus spike proteins of HKU1, OC43, NL63, or 229E could protect against SARS-CoV-2 in vitro.

28 Oct 2022

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

A new study confirmed that the SARS-CoV-2 spike protein does not bind to human AChR’s orthosteric sites, nor does it compete with ACh, choline, or nicotine.

28 Oct 2022

New breakthrough in understanding how deletion of certain genes can lead to cancer growth

Genetic mutations kick start cancers. Some mutations shuffle the genetic code, others come from the deletion of key genes.

28 Oct 2022

Low-density granulocytes are phenotypically altered in people with long-COVID

In a recent study posted to the bioRxiv* preprint server, researchers characterized low-density granulocyte (LDG) neutrophil (NP) proportion among individuals up to 14 months post-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection.

28 Oct 2022

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.

27 Oct 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

In a recent study posted to the bioRxiv* preprint server, researchers at Beth Israel Deaconess Medical Center assessed the immunogenicity associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.5 bivalent messenger ribonucleic acid (mRNA) vaccine boosters.

27 Oct 2022

RNA-sensing platform could help detect and selectively kill tumors, or edit the genome in specific cells

Researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT have developed a system that can detect a particular RNA sequence in live cells and produce a protein of interest in response.

27 Oct 2022

Long COVID, a new clinical entity constantly evolving

Researchers discuss the epidemiology, diagnosis, pathogenesis, and treatment of long COVID.

27 Oct 2022

Increased Gibbs energy of binding indicates greater infectivity of SARS-CoV-2 BA.2.75

Researchers explore the thermodynamic properties of the SARS-CoV-2 Omicron subvariant BA.2.75 to understand its increased transmissibility.

27 Oct 2022

New discovery may change the textbook model of GPCR-mediated signaling

Researchers at University of California San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs.

27 Oct 2022

Vaccination- and/or natural infection-induced immune responses against SARS-CoV-2 Omicron subvariants

Researchers comparatively evaluated the neutralization antibody titers for SARS-CoV-2 Omicron VOC subvariants BA.1, BA.2, BA.4/5 among individuals with ancestral B.1 strain infections, vaccinated individuals, or with hybrid immunity from breakthrough infections and vaccinations with Delta or Gamma VOCs.

27 Oct 2022

Monoclonal antibodies generated from COVID-19-recovered individuals shed light on the molecular basis of SARS-CoV-2 Omicron variant immune evasion

Researchers reported three human monoclonal antibodies generated from COVID-19-recovered individuals during the initial wave of the pandemic in India.

27 Oct 2022

Study finds that ACE-2 is not biochemically required for SARS-CoV2 membrane fusion

A study tested the hypothesis that the ACE-2 receptor of SARS-CoV-2 is not only an attachment factor in viral infection but also plays a role in activating the viral spike protein to facilitate membrane fusion.

27 Oct 2022

New studies point to a broadly applicable treatment for neurodegenerative diseases

Two new studies from Washington University School of Medicine in St. Louis support development of a broadly applicable treatment for neurodegenerative diseases that targets a molecule that serves as the central executioner in the death of axons, the wiring of the nervous system.

26 Oct 2022

What is the efficacy of RT-PCR assays for detection of SARS-CoV-2 in human semen?

A new study aimed to develop a standardized protocol for SARS-CoV-2 RNA detection in semen fractions used for assisted reproductive technology.

26 Oct 2022

COVID-19 and the gut

Researchers summarize current knowledge about underlying mechanisms and potential therapeutic approaches for the effects of COVID-19 on the gut.

26 Oct 2022

Enzyme News and Research

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

Ceria nanoparticles interfere with biological processes just like native enzymes

Researchers propose origin-of-life molecule as therapeutic target for tailored cancer therapies

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

New breakthrough in understanding how deletion of certain genes can lead to cancer growth

Low-density granulocytes are phenotypically altered in people with long-COVID

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

RNA-sensing platform could help detect and selectively kill tumors, or edit the genome in specific cells

Long COVID, a new clinical entity constantly evolving

Increased Gibbs energy of binding indicates greater infectivity of SARS-CoV-2 BA.2.75

New discovery may change the textbook model of GPCR-mediated signaling

Vaccination- and/or natural infection-induced immune responses against SARS-CoV-2 Omicron subvariants

Monoclonal antibodies generated from COVID-19-recovered individuals shed light on the molecular basis of SARS-CoV-2 Omicron variant immune evasion

Study finds that ACE-2 is not biochemically required for SARS-CoV2 membrane fusion

New studies point to a broadly applicable treatment for neurodegenerative diseases

What is the efficacy of RT-PCR assays for detection of SARS-CoV-2 in human semen?

COVID-19 and the gut

Understanding the DNA Damage Response in Innate Immunity eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo